Phase II Single-arm Study of Tepotinib Combined with Cetuximab


About this study

The purpose of this study is to assess the preliminary anti-tumor activity, safety, and tolerability, and to explore the pharmacokinetics (PK) of tepotinib in combination with cetuximab in participants with RAS/BRAF oncogene wild-type left-sided metastatic colorectal cancer (mCRC) having acquired resistance to anti-epidermal growth factor receptor (EGFR) antibody targeted therapy due to mesenchymal epithelial transition factor (MET) amplification.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Are ≥ 18 years of age (or having reached the age of majority according to local laws and regulations, if the age of majority is > 18 years of age) at the time of signing the informed consent.
  • Advanced (locally advanced or metastatic, unresectable) left-sided (from splenic flexure to rectum – National Comprehensive Cancer Network CRC Version 1.2021 guidelines) CRC with RAS/BRAF wild-type at study entry confirmed prior to enrollment, with previous antiEGFR therapy and acquired resistance on the most recent anti-EGFR monoclonal antibody therapy (panitumumab or cetuximab) by radiological documentation of disease progression according to RECIST Version 1.1.
  • MET amplification detected by a positive liquid biopsy and/or tissue with appropriate regulatory status (collected after disease progression of the previous anti-EGFR therapy).
  • Measurable disease by Investigator in accordance with RECIST Version 1.1.
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
  • Life expectancy > 3 months.
  • Participants having at least one systemic treatment for mCRC including 1 anti-EGFR monoclonal antibody therapy as the most recent line of therapy for mCRC before study treatment and must have shown a radiologically confirmed by RECIST Version 1.1 complete response (CR) or partial response (PR), both for at least 4 months or stable disease (SD) for at least 6 months to that therapy prior to disease progression.
    • For Cohort A in sites outside of US, participants must only have had one prior systemic treatment for mCRC;
    • For Cohort B in sites in the US only, participants must have had at least two prior systemic treatments for mCRC. First-line treatment must include a fluoropyrimidine and oxaliplatin or irinotecan and second-line treatment must include a fluoropyrimidine, oxaliplatin, or irinotecan.
  • Less than 2 months between the last administration of the most recent EGFR containing regimen and first dosing in this study.
  • Adequate hematological function in the absence of transfusions in 7 days before testing defined by white blood cell count ≥ 3 × 10^9 /L with absolute neutrophil count, ≥ 1.5 × 10^9 /L, platelet count ≥ 100 × 10^9 /L, and hemoglobin ≥ 8.5 g/dL.
  • Adequate hepatic function defined by a total bilirubin level ≤ 1.5 × upper limit of normal (ULN), AST ≤ 3 × ULN, and ALT ≤ 3 × ULN. For participants with liver metastases: total bilirubin ≤ 1.5 × ULN, AST/ALT ≤ 5 × ULN.
  • Adequate renal function defined by an estimated glomerular filtration rate > 30 mL/min according to the 4-component Modification of Diet in Renal Disease (MDRD) equation (GFR [mL/min/1.73 m2 ] = 175 × serum creatinine (Scr)-1.154 × age-0.203 × 1.212 [if African American] × 0.742 [if female]).
  • Are male or female Contraceptive use by males or females will be consistent with local regulations on contraception methods for those participating in clinical studies:
    • Male Participants: Agree to the following during the study intervention period and for at least 4 months after the last dose of study intervention:
    • Refrain from donating sperm PLUS, either:
    • Abstain from intercourse with a woman of child bearing potential; OR
    • Use a male condom:
    • When having sexual intercourse with a woman of child bearing potential, who is not currently pregnant, and advise her to use a highly effective contraceptive method with a failure rate of < 1% per year, since a condom may break or leak;
    • Female Participants:
    • Are not pregnant or breastfeeding, and at least one of the following conditions applies:
    • Not a woman of child bearing potential; OR
    • If a woman of child bearing potential, use a highly effective contraceptive method (i.e., with a failure rate of < 1% per year), preferably with low user dependency, for the following time periods:
    • Before the first dose of the study intervention(s), if using hormonal contraception: o Has completed at least one 4-week cycle of an oral contraception pill and either had or has begun her menses OR o Has used a depot contraceptive or extended-cycle oral contraceptive for least 28 days and has a documented negative pregnancy test using a highly sensitive assay; AND a barrier method,
    • During the intervention period;
    • After the study intervention period (i.e., after the last dose of study intervention is administered) for at least 2 months after the last dose of study intervention and agree not to donate eggs (ova, oocytes) for reproduction during this period;
    • The investigator evaluates the effectiveness of the contraceptive method in relationship to the first dose of study intervention;
    • Have a negative serum or highly sensitive urine pregnancy test, as required by local regulations, within 24 hours before the first dose of study intervention. If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required;
    • The investigator reviews the medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a female with an early undetected pregnancy.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.
  • Participants with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS metastases. Also excluded are participants with carcinomatous meningitis.
  • Participants who have brain metastasis as the only measurable lesion.
  • Prior chemotherapy, biological therapy, radiation therapy, hormonal therapy for anti-cancer purposes, targeted therapy, or other investigational anticancer therapy (not including palliative radiotherapy at focal sites) within 21 days prior to the first dose of study intervention, except for the anti-EGFR containing regimen including associated chemotherapy if applicable, which may be continued until enrollment of the participant in the study.
  • Any unresolved toxicity Grade 2 or more according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, from previous anticancer therapy excluding neuropathy, alopecia and rash.
  • Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 NCI-CTCAE v 5.0), any history of anaphylaxis, or uncontrolled asthma (i.e., 3 or more occurrences of partially controlled asthma).
  • Discontinuation of the most recent cetuximab or panitumumab containing therapy due to an adverse event.
  • Prior treatment with other agents targeting the HGF/MET pathway.
  • Impaired cardiac function:
    • Left ventricular ejection fraction < 45% defined by echocardiography (a screening assessment not required for participants without a history of congestive heart failure unless clinically indicated);
    • Serious arrhythmia;
    • Unstable angina pectoris;
    • New York Heart Association heart failure Class III and IV;
    • Myocardial infarction within the last 12 months prior to study entry;
    • Symptomatic pericardial effusion;
    • Corrected QT interval by Fridericia (QTcF) > 480 ms.
    • Hypertension uncontrolled by standard therapies (not stabilized to < 150/90 mmHg).
  • Past or current history of neoplasm other than mCRC, except for curatively treated nonmelanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively treated and with no evidence of disease for at least 5 years.
  • Medical history of difficulty swallowing, malabsorption, or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the test products.
  • Major surgery within 28 days prior to Day 1 of study intervention. 
  • Known infection with human immunodeficiency virus, or an active infection with hepatitis B or hepatitis C virus.
  • Substance abuse, active infection, or other acute or chronic medical or psychiatric condition or laboratory abnormalities that might increase the risk associated with study participation at the discretion of Investigators.
  • IMP use in another study within 3 weeks of the first dose of study intervention.
  • History of ILD or interstitial pneumonitis including radiation pneumonitis that required steroid treatment.

Eligibility last updated 8/26/21. Questions regarding updates should be directed to the study team contact.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Zhaohui Jin, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office


Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Tanios Bekaii-Saab, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Mayo Clinic Footer